lobbying_activities: 2343456

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2343456	1d4ddacd-fcf7-49dc-87aa-505688bcc78c	Q3	MARSHALL & POPP, LLC	401105121	PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA	2019	third_quarter	PHA	Issues related to prescription drug value - S.2543: Prescription Drug Pricing Reduction Act of 2019; H.R.3: Lower Drug Costs Now Act of 2019. Biosimilars. Importation of prescription drugs. 340B issues. FDA regulatory issues, including the International Pricing Index and Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals.	Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),Office of Management & Budget (OMB),White House Office	50000		0	0	2019-10-16T09:10:27.567000-04:00